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Abstract
Background: The clinical course of human papillomavirus (HPV) associated with Bowenoid papulosis and condyloma 
acuminatum of anogenital tumors are still unknown. Here we evaluated molecules that are relevant to cellular 
proliferation and regulation of apoptosis in HPV associated anogenital tumors.
Methods: We investigated the levels of telomerase activity, and inhibitor of apoptosis proteins (IAPs) family (c-IAP1, c-
IAP2, XIAP) and c-Myc mRNA expression levels in 20 specimens of Bowenoid papulosis and 36 specimens of 
condyloma acuminatum in anogenital areas. Overall, phosphorylated (p-) AKT, p-ribosomal protein S6 (S6) and p-4E-
binding protein 1 (4EBP1) expression levels were examined by immunohistochemistry in anogenital tumors both with 
and without positive telomerase activity.
Results: Positive telomerase activity was detected in 41.7% of Bowenoid papulosis and 27.3% of condyloma 
acuminatum compared to normal skin (p < 0.001). In contrast, the expression levels of Bowenoid papulosis indicated 
that c-IAP1, c-IAP2 and XIAP mRNA were significantly upregulated compared to those in both condyloma acuminatum 
samples (p < 0.001, p < 0.001, p = 0.022, respectively) and normal skin (p < 0.001, p = 0.002, p = 0.034, respectively). 
Overall, 30% of Bowenoid papulosis with high risk HPV strongly promoted IAPs family and c-Myc but condyloma 
acuminatum did not significantly activate those genes. Immunohistochemically, p-Akt and p-S6 expressions were 
associated with positive telomerase activity but not with p-4EBP1 expression.
Conclusion: Combined analysis of the IAPs family, c-Myc mRNA expression, telomerase activity levels and p-Akt/p-S6 
expressions may provide clinically relevant molecular markers in HPV associated anogenital tumors.
Background
Telomerase is a ribonucleoprotein reverse transcriptase
(RT) complex that adds telomeric TTAGGG repeat
sequences to chromosomes by using an intrinsic RNA
component as template [1,2]. Human telomerase consists
of RNA components and a catalytic subunit of human
telomerase RT (hTERT), and is coimmunoprecipitated
with Akt kinase, heat shock protein 90, the mammalian
target of rapamycin (mTOR), and p70 ribosomal protein
S6 kinase 1 (S6K1) [3]. Transcription factors c-Myc, SP1,
estrogen receptor, E2F-1, WT-1, NFκB and MZF-2 are
i n v o l v e d  i n  r e g u l a t i o n  o f  h T E R T  g e n e  e x p r e s s i o n  [ 4 ] .
Telomerase activity (TA), an indicator of cellular immor-
talization, is considered to at least partly responsible for
the unlimited replication seen in immortalized cells [1,5].
Previous studies have shown that malignant skin neopla-
sias, including melanoma, exhibit high levels of TA com-
pared to benign skin conditions [6]. High levels of TA in
such malignant cells may act to maintain stable telomere
lengths [7].
In general, cutaneous tumors of the anogenital area are
usually associated with human papillomaviruses (HPVs).
High and low risk HPV types are usually detected in
Bowenoid papulosis (BP) and condyloma acuminatum
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(CA), respectively. BP is a rare skin neoplasia, which is
found in the anogenital area as multifocal papular lesions.
In contrast, CA occasionally occurs as pigmented nod-
ules or papules in the anogenital area, resulting some-
times in its misdiagnosis as BP [8]. Overall, high and low
risk HPV types were sometimes found in BP [9,10].
Recently, E6 oncoproteins belonging to high risk HPV
types were shown to increased TA in epithelial cells, pre-
dominantly by inducing transcription of the hTERT gene
[11]. In BP and CA, some anogenital tumors show rapid
growth and mitosis, while others show spontaneous
remission. Therefore, it is clinically difficult to determine
whether it is necessary to treat HPV associated anogeni-
tal tumors.
The phosphorylated (p-) proteins associated with cell
signaling pathways, e.g., Akt, 4E-binding protein 1
(4EBP1) and ribosomal protein S6 (S6), provide prolifera-
tive signals, promote survival and regulate protein syn-
thesis [12]. Among these proteins, protein kinase Akt is
activated by phosphorylation of threonine 308, and serine
473 has been shown to be important in mediating cell
proliferation and inhibiting apoptosis in several tissues
and cancers [13,14]. The Akt activates many downstream
factors, including mTOR, which in turn activates 4EBP1
and p70S6K1. The 4EBP1 and p70S6K1 play a critical role
in controlling ribosomal protein synthesis during cell
proliferation [15,16] through the phosphorylation of
eukaryotic initiation factor 4E and S6, respectively. How-
ever, expression of p-AKT, p-S6 and p-4EBP1 in anogeni-
tal tumors has not been previously reported.
Recently, inhibitors of apoptosis protein (IAP) family
members, e.g., c-IAP1, c-IAP2 and XIAP, were reported
to act as tumor markers and were used as prognostic fac-
tors for estimating the survival of cancer patients. There
is a large body of data demonstrating elevated expression
of IAP proteins in many human cancers [17-19]. Among
them, cervical cancer cells with high risk HPV types have
been investigated for the expression of IAPs family
[20,21], however, there are no reports about the expres-
sion of those genes of HPV associated anogenital tumors.
The majority of HPV associated tumor cells possess
active TA, and a combination of active TA and high risk
HPV oncogene proteins E6 and E7 contributes to the
immortalization of primary epithelial cells. The E6 of
HPV directly interacts with c-Myc, and the complex acti-
vates hTERT expression [11]. Recently, the transcription
of c-IAP2, a member of the IAP protein family, was
shown to be significantly upregulated by E6 and E7 onco-
proteins in cells infected with high risk type HPV 16, but
not in cells infected with low risk type HPV 6. Among
IAPs family members, c-IAP2 is related to hTERT protein
and promotes hTERT as well as c-Myc activity in E6 of
HPV 16 [22]. To evaluate molecules relevant to cellular
proliferation and immortalization, we examined the
expression of the IAPs family members and c-Myc in CA
and BP by real time RT-PCR. In addition, we present the
TA level and correlate a positive TA with the frequency of
p-Akt, p-S6 and p-4EBP1 expression in these tumors.
Methods
Patients and tissues samples
A total of 74 samples (36 CA, 20 BP, and 18 normal skin
(NS)) obtained from 74 Japanese patients were examined
in the current study. Biopsy or surgical specimens were
collected at the Department of Dermatology, Nippon
Medical School, Japan. Initially, 12 BP and 22 CA speci-
mens were collected and were immediately placed in liq-
uid nitrogen and stored at - 80°C until proteins and DNAs
extraction. A second portion of each samples was fixed in
10% buffered formalin solution and embedded in paraffin
for histopathologic examination, and immunohistochem-
istry. Eight BP and 14 CA samples were collected to
examine the expression of IAPs family and c-Myc by real
time RT-PCR. In addition, initial remained 2 BP and 1
CA frozen samples were used for real time RT-PCR. Sam-
ples of NS were collected from a remainder of non sun-
exposed skin, which was used as donor skin for perform-
ing a skin graft. None of the donor patients had a history
of lymphatic disorders or exhibited active atopic dermati-
tis. Informed consent was obtained from each patient,
and the study was approved by the Ethical Committee at
Nippon Medical School and National Institute of Infec-
tious Diseases.
Preparation of tissue extracts
The frozen tissues consisting of 12 samples out of 20 BP,
22 samples out of 36 CA, and 14 samples out of 18 nor-
mal skin were added in ice lysis buffers and homogenized
gently {(105 cells/20 μl) in ice-cold lysis buffer [10 mM
tris-HCl (pH 7.5), 1 mM MgCl2 1 mM EDTA, 0.1 mM
PMSF, 5 mM β-mercaptoethanol, 0.5% 3-[(3-Cholamido-
propyl)dimethylammonio]-1-propane-sulfonate
(CHAPS), and 10% glycerol]}. The suspension was incu-
bated for 30 min on ice and then centrifuged at 100,000 g
for 30 min at 4°C. The supernatant was removed and the
protein concentration was determined by the Bradford
assay (Bio-Rad, Hercules, CA).
Nonradioisotope telomere repeat amplification protocol 
(TRAP) assay
Telomerase activity (TA) was assayed by the TRAP
method in a total volume of 25 μl, as previously described
[5,23,24]. In brief, aliquots of untreated cell extract were
incubated with 0.1 μg of TS oligonucleotide primer (5'-
AATCCGTCGAGCAGAGTT-3') for 20 min at 22°C in
the following reaction mixture: 20 mM Tris-HCl (pH 8.3),
1.5 mM MgCl2, 63 mM KCl, 0.005% Tween-20, 1 mM
EDTA, 50 μM dNTPs, 1 μg of T4 gene 32 protein (Roche,Mitsuishi et al. BMC Cancer 2010, 10:118
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Mannheim, Germany), and 0.1 mg/ml BSA. Following
elongation of the TS oligonucleotide primer by telom-
erase, the mixture was incubated at 95°C for 5 min prior
to the addition of 5 units of Taq  polymerase and 0.1 μg
CX oligonucleotide primer (5'-CCCTTACCCTTAC-
CCTTACCCTAA-3'). The elongated products were
amplified by PCR (30 cycles at 94°C for 30 s, 50°C for 30 s,
and 72°C for 60 s). One-fourth of each reaction product
was then analyzed by electrophoresis in 1× Tris-glycine
on 12.5% polyacrylamide nondenaturing gels and visual-
ized with SYBR Green DNA stain (BMA Rockland, ME,
USA). Internal telomerase assay standard (ITAS) was
used as an internal control [25].
Quantification of enzyme activity
Quantification of enzyme activity in samples was deter-
mined using NIH imaging software [25]. In brief, the sig-
nal intensity of each band on the TRAP ladders was
measured individually. These values were compared with
TRAP products obtained with known amounts of control
extract, assayed in parallel. The relative specific TA of
each sample is expressed as a percentage of the specific
activity of the control extracts. An extract of EB virus
transformed B cell lines (Namalva cells) was used as a
positive control. We estimated that more than 20% of rel-
ative TA value mean having significant enzymatic activity
in individual sample compared with Namalva cells and
normal skin samples by calculating with NIH imaging
soft ware.
Real Time RT-PCR and gene expression analysis
Real time RT-PCR was performed in order to evaluate the
differences in the expression of IAPs family members (c-
IAP1, c-IAP2, X-IAP) and c-Myc between BP, CA and
NS. The frozen tissues (10 of 20 BP samples, 15 of 36 CA
samples, and 4 of 18 NS samples) were used for real time
RT-PCR and gene expression analysis. The mRNA tran-
scripts of the IAPs family members and c-Myc were
quantified using the quantitative kinetic reverse tran-
scription PCR methodology (Applied Biosystems, Foster
City, CA) and Taqman chemistry (Roche Applied Sci-
ence, Penzberg, Germany). All expression levels were
normalised to the expression of the housekeeping gene,
GAPDH. Total RNA was extracted from the skin samples
using an RNAqueous Kit (Ambion, Austin, TX) and
treated with TURBO DNA-free  (Ambion, Austin, TX)
according to the manufacturer's protocols. The prepared
RNAs were subjected to real time PCR using an Mx3005P
thermocycler (Strategene, San Diego, CA) and a Quanti-
Tect Multiplex RT-PCR Kit (Qiagen, Valencia, CA) [26].
Plasmids were assayed along with the tissue RNAs and
used to construct standard curves. The specific probes
and primers that were used are shown in Table 1.
Immunohistochemistry
A total of 22 CA (5 with and 17 without TA) samples and
12 BP (5 with and 7 without TA) samples were analysed
for telomerase activity were also examined immunohis-
tochemically in order to compare the expression of p-Akt
thr308, p-S6 and p-4E binding protein 1(4EBP1). Rabbit
polyclonal antibodies against p-Akt thr308 (Santa Cruz
Biotechnology, Santa Cruz, CA, #sc-16646-R,
dilution1:400), p-S6 ser235/236 (Cell Signaling Technol-
ogy, Danvers, MA, #2211, 1:200), and p-4EBP1 thr70
(Cell Signaling Technology, #9455, 1:50) were used.
Immunohistochemistry was performed on the tissue sec-
tions from tumours with high or low TA that were
mounted on aminopropyltriethoxysilane-treated slides
(Matsunami Glass Ind., LTD., Osaka, Japan), as previ-
ously described [27].
Immunohistochemical evaluation
The stained sections were independently examined by
two of the authors (F.O. and Y. Y.). The labelling index of
p-Akt thr308, p-S6, and p-4EBP1 was determined by
assessing the number of stained cells within the relevant
area of a selected section containing more than 50 intra-
epidermal cells, and at least 4 random microscopic fields
at 200× magnification were evaluated. After counting
both immunoreactive cells and the total number of intra-
epidermal cells, the average percentage of immunoreac-
tive cells was calculated without knowledge of the clinical
data. The percentage of positive cells was arbitrarily
scored as follows: 0, <30%; 1, 30% to 60%; 2, >60% [28].
Western blot
Western blot analysis and reverselysate protein rays were
performed in anogenital tumors samples. Proteins were
resolved on a polyacrylamide gel and transferred to a
polyvinylidene difluoride (PVDF) membrane (Bio-Rad,
Hercules, CA). The membrane was incubated with the
primary antibodies and then the HRP-conjugated anti-
rabbit IgG antibody. Immunoreactive bands were visual-
ised with the ECL Plus Detection Reagent according to
the manufacturer's protocol (GE Healthcare Bio-Sci-
ences, Piscataway, NJ).
Detection of HPV DNA and typing
Available frozen tissues from 10 BP and 10 CA samples
were digested with proteinase K (100 mg/ml) in the pres-
ence of 0.5% SDS for 2 h at 65°C, and extracted with phe-
nol-chloroform-isoamyl alcohol. The DNAs were then
precipitatedin ethanol as previously described [29]. Total
cellular DNA was used for PCR amplification using
L1C1/L1C2(C2 m) primers [30]. The primer sets are able
to amplify majority of mucosal HPV types including
types 6 and 16. The HPV type was determined by com-
paring the restriction fragment length polymorphismMitsuishi et al. BMC Cancer 2010, 10:118
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Table 1: Sequences of specific probes and primers for real time RT-PCR
Gene Application Sequence Length (bp) 5' 3' Tm (°) Genebank 
accession 
number
GAPDH P AAC AGC GAC ACC CAC 
TCC TCC ACC
24 FAM BHQ1 67.4 NM_002046
F ACC AGG TGG TCT CCT 
CTG AC
20 58.5
R TGT AGC CAA ATT CGT 
TGT CAT ACC
24 58.6
c-IAP1 P AGG AAA TGC TGC GGC 
CAA CAT CTT CA
26 ROX BHQ2 66.8 NM_001166
F GAG AGA ACT GAT TGA 
TAC CAT TTT GG
26 57.6
R AGA CCT GAA ACA TCT 
TCT GTT GG
23 57.3
c-IAP2 P TCC GTC AAG TTC AAG 
CCA GTT ACC CTC A
28 Cy5 BHQ3 67.2 NM_001165
F CTT GAT AAG AAT TAA 
AGG ACA GGA GTT C
28 58.0
R TGG GCT GTC TGA TGT 
GGA TAG
21 57.5
XIAP P CAG TGA AGA CCC TTG 
GGA ACA ACA TGC T
28 HEX BHQ1 66.7 NM_001167
F GGA GGA GGG CTA ACT 
GAT TGG
21 58.1
R TAT TCT TGT CCC TTC 
TGT TCT AAC AG
26 57.9
c-Myc P CCA CCA CCA GCA GCG 
ACT CTG AGG A
25 HEX BHQ1 69.0 NM_002467
F GGT GCT CCA TGA GGA 
GAC AC
20 58.1
R CCA GCA GAA GGT GAT 
CCA GAC
21 58.7
P; Probe, F; Forward, R; ReverseMitsuishi et al. BMC Cancer 2010, 10:118
http://www.biomedcentral.com/1471-2407/10/118
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(RFLP) pattern of the amplified sequences with those
deduced from sequences of known HPV types in Gen-
bank or EMBL Databank [30].
Statistical methods
The differences between the cases were assessed using χ2
analyses to compare categorical variables and the Mann-
Whitney U test to compare continuous measures. Statis-
tical analysis was carried out using the SPSS software
package (SPSS Inc., version 17.0, Chicago, IL, USA). A
two-sided test with a significance level of 0.05 was used to
determine statistical significance for all analyses.
Results
Histopathologic examination
Histopathologic examination of 20 BP showed the pres-
ence of several dyskeratotic keratinocytes in a thickened
epidermis with hyperchromatic nuclei. There were no
significant histopathologic differences in 20 BP. In con-
trast, moderate to considerable acanthosis, with thicken-
ing and elongation of the rete ridges, contained many
vacuolated cells of the stratum malpihii in 36 CA sam-
ples. These CA samples did not show typical Bowenoid
changes. The anogenital tumors had equivalent numbers
of keratinocytes and/or dyskeratotic keratinocytes.
Telomerase activity
Epstein-Barr (EB) virus transformed B cell lines (Namalva
cells) and normal skin were used as positive and negative
control, respectively. All the normal control skin samples
e xhibited very low or absent T A when using the same
amount of protein (1 μg) for telomerase assay. In contrast,
Namalva cells showed high TA and regarded as a 100%
relative TA value. Moderate to high TA levels were visual-
ized in 41.7% (5 out of 12) BP samples when compared to
CA (p = 0.025) and normal non sun-exposed skin (p <
0.001). In contrast, 22.7% (5 out of 22) CA samples
showed positive TA compared to normal non sun-
exposed skin (p < 0.001) (Figure 1). Among anogenital
tumors, high TA levels corresponding to greater than 40%
of relative TA were detected in 25% (3 out of 12) BP sam-
ples, but none of the 22 CA samples.
Detection of low risk or high risk of HPV DNA
Available10 BP and 10 CA samples were examined to
determine the presence of HPV DNA by performing the
PCR assay. Low risk type HPV 6 was detected in all of the
CA samples, while high risk types HPV 16 and HPV 31
were detected in 9 BP samples and 1 BP sample, respec-
tively.
C-IAP1, C-IAP2 and XIAP mRNA expression
c-IAP1, c-IAP2, and XIAP were significantly upregulated
in the BP samples compared to 15 CA samples (c-IAP1, p
< 0.001; c-IAP2, p < 0.001; XIAP, p = 0.022; Figure 2A, B,
C). Similarly, c-IAP1, c-IAP2, and XIAP mRNA levels in
BP samples were significantly up-regulated compared to
NS (c-IAP1, p  < 0.001; c-IAP2, p  = 0.002; XIAP, p  =
0.034). To estimate the mRNA expression of the IAPs
family, each BP sample was carefully examined in tripli-
cate. Three of 10 BP cases (Cases 6, 7 and 10) showed a
higher expression level of the IAP family members com-
pared to other samples (vs. other BP (n = 7); c-IAP1, p <
0.001; c-IAP2, p < 0.001; XIAP, p < 0.001; and vs. CA (n =
15); c-IAP1, p  < 0.001; c-IAP2, p  < 0.001; XIAP; p  <
0.001).
A l t h o u g h  m o r e  t h a n  2 7 . 3 %  o f  C A  s a m p l e s  d e m o n -
strated positive TA, c-IAP1, c-IAP2, and XIAP expression
levels were not significantly up-regulated when compared
to the high expression levels observed in BP. This results
suggested that the oncogenic proteins expressed by low-
risk HPV types did not activate c-IAP1, c-IAP2 or XIAP.
The expression levels of c-IAP1, c-IAP2 and XIAP in CA
were similar to the levels seen in NS (c-IAP1, p = 0.052; c-
IAP2, p = 0.876; XIAP, p = 0.098). Two of 15 CA samples
(Cases 12 and 13) demonstrated an increased expression
of only XIAP compared to NS samples, but this expres-
sion was a rare event in other CA samples.
Figure 1 The analysis of telomerase activity (TA) in the samples of 
Bowenoid papulosis, condyloma acuminatum, and normal skin 
by a nonisotopic PCR-based TRAP assy. The box plot of relative te-
lomerase activity among Bowenoid papulosis, condyloma acumina-
tum, and normal skin. Box plots show median, 25th and 75th 
percentiles and range. The extreme values were noted as dots and 
stars. Bowenoid papulosis samples had a significantly higher relative 
levels of TA than those with condyloma acuminatum and normal skin 
samples (condyloma acuminatum; p = 0.025, normal skin; p < 0.001, 
Mann-Whitney U test, two-sided).
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C-Myc mRNA expression
c-Myc mRNA expression showed significant differences
between BP and CA samples (p < 0.001; Figure 2D). Simi-
lar to above, all measurements were performed in tripli-
cate. Of 10 BP and 15 CA samples examined, 3 BP cases
(Cases 6, 7 and 10) had significantly higher c-Myc expres-
sion compared to other samples (vs. other BP (n = 7); c-
Myc, p < 0.001; and vs. CA (n = 15); c-Myc, p < 0.001).
These three cases also showed higher expression levels of
c-IAP1, c-IAP2 and XIAP mRNA, suggesting the poten-
tial for a high level of malignancy. These results are con-
sistent with those of a previous study, which suggested
that HPV E6 directly interacts with c-Myc and that c-
Myc/E6 complex activates hTERT expression [11]. Simi-
lar to the levels of c-IAP1, c-IAP2 and XIAP, mRNA
expression level of c-Myc was elevated in BP compared to
NS samples (p = 0.010). In contrast, c-Myc expression in
CA was similar to that of NS (p = 1.000).
Figure 2 Quantitative real time RT-PCR analysis of (A) c-IAP1 (B) c-IAP2, (C) XIAP and (D) c-Myc in Bowenoid papulosis, condyloma acumi-
natum, and normal skin. The relative expression was calculated as the expression of the IAPs or c-Myc normalised to the expression of GAPDH. Each 
experiment was performed three times, and data are shown as box and whisker plots. The expression of (A) c-IAP1, (B) c-IAP2, (C) XIAP and (D) c-Myc 
was significantly higher in Bowenoid papulosis compared with condyloma acuminatum and normal skin. (A; condyloma acuminatum; p < 0.001, nor-
mal skin; p < 0.001 B; condyloma acuminatum; p < 0.001, normal skin; p = 0.002 C; condyloma acuminatum; p = 0.022, normal skin; p = 0.034 D; con-
dyloma acuminatum; p < 0.001, normal skin; p = 0.01, Mann-Whitney U test, two-sided). In contrast, no significant difference in the expression of the 
IAP family members or c-Myc was detected between condyloma acuminatum and normal skin.
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P-Akt 308, P-S6 and P-4EBP-1 expression
p-Akt expression was observed in the cytoplasm and
nucleus of the intraepidermal cells (Figure 3A), while p-
4EBP1 expression was mainly observed in the nucleus of
intraepidermal cells (Figure 3B) and p-S6 expression was
predominantly observed in the cytoplasm or at the edge
of the nucleus (Figure 3C). The expression percentage
was based on the estimated number of intraepidermal
cells in each tissue section with positive staining, either in
the nucleus or cytoplasm. Of 34 cases examined, BP and
C A  s p e c i m e n s  w i t h  T A  c l e a r l y  d e m o n s t r a t e d  a n
increased incidence of both p-Akt expression (Figure 4A)
and p-S6 expression (Figure 4B) compared to those sam-
ples without TA. In contrast, p-4EBP1 expression was not
different between the anogenital tumors with or without
TA (Figure 4C). Non sun-exposed normal skin demon-
strated weak and occasionally moderate staining that was
primarily localized to the basal layer (data not shown). In
summary, there are differences in p-Akt308 and p-S6
expression, but not p-4EBP1 expression, between ano-
genital tumors with and without TA.
Discusssion
Although a broad range of malignancies was investigated,
telomerase activity (TA) of a comparative study has not
been reported in Bowenoid papulosis (BP) and condy-
loma acuminatum (CA) of anogenital tumors. Despite of
the infection with high risk HPV , BP sometimes shows
spontaneous regressions within a few months. However,
BP may transform into squamous cell carcinoma (SCC) of
the genitalia but the mechanism for the development of
SCC from BP has not been defined [8]. In contrast, CA is
also infected with HPV which is low risk HPV types 6 or
11. Overall, giant CA is occationally considered a low
grade of SCC [8]. The BP and CA are little known regard-
ing the molecular mechanisms involved in malignant
transformation or spontaneous remission based on the
biological alterations of the cell cycle, cell signaling and
apoptosis.
In order to identify if HPV is associated with TA in BP
and CA of anogenital tumors, samples were tested by
TRAP assay. The typical ladder pattern was detected.
Positive TA was detected in 41.7% (5 of 12) BP samples
and 22.7% (5 of 22) CA samples (p = 0.025). These results
suggest that higher telomerase activity is correlated with
high risk HPV associated BP compared to low risk HPV
associated CA. There was no evidence of increased TA in
normal skin (NS) from non-sun-exposed areas. Initially,
we hypothesised that increased TA could be an important
tumor marker for malignant potential. As expected, this
study showed a higher frequency of increased TA in BP
compared with CA. Importantly, increased TA was also
found in 22.7% (5 out of 22) CA samples that were associ-
ated with low-risk HPV. In general, low levels of TA are
present in non-malignant skin conditions [6]. Hiyama et
al. demonstrated that leukocytes constitutively express
low levels of TA [31]. Therefore, this study suggested that
CA with TA may be an intermittent phenomenon and
that the presence of low risk HPV s was not associated
with increased TA. Overall, current study suggested that
only the high risk HPV E6 and E7 genes increased TA in
anogenital tumors.
The expression of the c-Myc gene is important for cell
proliferation in HPV associated cutaneous lesions. The c-
Myc gene acts directly or indirectly through its interac-
tion with p53 and E6 oncoproteins, and plays an impor-
tant role for the induction of hTERT protein [9]. In
contrast, IAPs family (XIAP, c-IAP1 and c-IAP2) can sup-
press apoptosis induced by a variety of apoptotic triggers.
The IAPs family can inhibit the downstream components
of caspase activation pathways that regulate apoptosis.
Some studies have established a circumstantial associa-
tion between the IAPs family and cancer. The overexpres-
sion of several family members has been detected in
several classes of human cancers [32,33]. Among IAPs
family, c-IAP2 is related to the hTERT protein and pro-
Figure 3 Western blot analysis and immunohistochemical analy-
sis for P-Akt thr308 (A), P-4EBP1 (B) and P-S6 (C) in Bowenoid pap-
ulosis and condyloma acuminatum. Western blot validation of 
immunohistochemical stainings showed a good correlation. Cases b 
and c which exhibited more than 30% expressions of p-Akt thr308 and 
p-S6, showed the intensity bands using frozen samples. In contrast, 
more than 30% expression of p-4EBP1 was detected, with double 
bands at 15 and 20 kDa in Cases b and c. The expression score indicates 
0, >30%; 1, 30% to 60%; 2, >60%. Scale bars = 100 μm.
A
C
BMitsuishi et al. BMC Cancer 2010, 10:118
http://www.biomedcentral.com/1471-2407/10/118
Page 8 of 10
motes hTERT expression [22]. According to one study,
overexpression of E6/E7 was found in high risk types
HPV 16 and 18, but not in low risk type HPV 6, and an
activated c-IAP2 promoter was found in E6/E7-immor-
talized human keratinocytes [22]. We quantitated the
expression of IAPs family and c-Myc mRNA using real
time RT-PCR assay in 10 BP and 15 CA samples. The lev-
els of IAPs family members (c-IAP1, c-IAP2 and XIAP)
and c-Myc mRNA expression in BP samples were higher
than those in CA and normal skin samples (Figure 2). The
mRNA expression levels were carefully determined by
performing triplicate assays. Of interest, 30% (Cases 6, 7
and 10) of BP showed significantly high expression of c-
IAP1, c-IAP2 and XIAP genes compared to the other
samples. Increased c-Myc expression was also found in
30% (Cases 6, 7, and 10) of BP, and was not observed in
CA samples. These results supported that some BP with
high risk HPV types have high levels of antiapoptosis,
while CA does not have such characteristics. In Cases 6, 7
and 10, it would be necessary to remove the lesional skin,
because BP may undergo transformation into SCC. In
contrast, the low expression of mRNA IAPs family mem-
bers in other BP and CA samples suggested limited cell
proliferation and a possible tendency toward spontane-
ous remission.
The phophatidylinositol-3 kinase (PI3K)/Akt signaling
pathway plays a central role in diverse cellular functions,
including proliferation, growth, survival and metabolism.
In general, Akt promotes protein synthesis and cell
growth by alleviating TSC1/2 suppression of the mam-
malian target of rapamycin (mTOR), allowing the latter to
act as part of the mTOR-raptor complex on 4E-binding
protein 1 (4EBP1) and ribosomal protein S6 (S6) [34].
Both S6 and p70S6 kinase1 are present downstream in
the Akt signaling pathway, which is not linearly associ-
ated with 4EBP1 phosphorylation [35]. To date, altera-
tions of the Akt/mTOR pathway have been observed in
numerous types of carcinomas, but little has been
reported about Akt/mTOR signaling in skin tumors. In
the current study, although p-4EBP1 expression did not
differ between CA and BP with or without positive TA, p-
Akt and p-S6 were expressed significantly more often in
BP and CA with increased TA than in CA and BP without
TA. This result suggested that positive TA is associated
with activated p-Akt and p-S6 expression but not with p-
4EBP1 expression. Overall, we speculated that HPV asso-
ciated anogenital tumor cells with increased TA could be
correlated with activation of Akt/mTOR/p70S6K1/S6 sig-
naling pathway but not with 4EBP1 signaling pathway. In
fact, S6 and 4EBP1 are located in the downstream of Akt
but they are different signal pathways [34,35].
Conclusion
Our study showed there were differences between TA
levels in BP and CA of anogenital tumors. A minority of
BP samples with high risk HPV types showed increased
c-Myc and IAPs family mRNA expression, whereas CA
samples with low risk HPV types showed little increase in
those genes. These results provided the majority of CA
even if they have increased TA and/or positive proteins
expression in cell signaling pathway, this may be transient
or intermittent phenomenon and may be indicative of
future apoptosis. The majority of BP lesions in this study
showed low levels of TA and mRNA expression of IAPs
family and c-Myc, suggesting most of BP were considered
to be less aggressive tumors. However, BP with high TA
levels and increased mRNA expression of IAPs family
and c-Myc may develop into SCC. Therefore, overexpres-
sion of IAPs family and c-Myc are also important in
affecting cancer progression. Combined estimation of cell
Figure 4 P-Akt thr308, P-S6 and P-4EBP1 expressions in relation with telomerase activity. Box graphs comparing positive telomerase activity 
(TA) for (A) P-Akt thr308, (B) P-S6 and (C) P-4EBP1 expressions in Bowenoid papulosis with and without TA (A; p = 0.004, B; p = 0.012, C; p = 0.807, Mann-
Whitney U test, two-sided) and in condyloma acuminatum with and without TA (A; p = 0.001, B; p = 0.001, C; p = 0.307, Mann-Whitney U test, two-
sided).
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growth and apoptosis-regulating proteins may provide
clinically relevant molecular markers in HPV associated
anogenital tumors.
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